Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 39 - General protective or antinoxious agents
Patents for A61P 39 - General protective or antinoxious agents (19,019)
06/2003
06/24/2003US6582747 Dry cocoa mix containing a mixture of non-alkalized and alkalized cocoa solids
06/19/2003WO2003050252A2 Heme-regulated eukaryotic initiation factor 2 alpha kinase knockout mice and methods for use
06/19/2003WO2003049675A2 Treating muscle wasting with selective androgen receptor modulators
06/19/2003WO2003005960A3 Novel bicyclic and tricyclic cannabinoids
06/19/2003US20030114478 Asthma therapy; antiinflammatory agents
06/19/2003US20030113840 25 human secreted proteins
06/19/2003US20030113278 Treatment of excessive radiation (e.g. sunburn) exposure
06/19/2003US20030111087 Process for the isolation of a major harmful oxidant from cigarette smoke
06/19/2003CA2469679A1 Heme-regulated eukaryotic initiation factor 2 alpha kinase knockout mice and methods for use
06/19/2003CA2469340A1 Treating muscle wasting with selective androgen receptor modulators
06/18/2003EP1318836A2 Treatment of hyperproliferative diseases
06/18/2003EP1318817A1 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals
06/18/2003EP1228075B1 Silicon compounds derived from ascorbic acid
06/18/2003CN1424910A IL-8 receptor antagonists
06/18/2003CN1111357C Food products having enhanced cocoa polyphenol content and processes for producing same
06/12/2003WO2003047367A1 Solid and stable creatine/citric acid composition(s) and compositions containing carbohydrate(s) or hydrates thereof, method for the production and use thereof
06/12/2003US20030109566 Therapeutic treatment of diseases in optic nerve and the like.
06/12/2003US20030109565 Administered by any means other than orally, characterized in that it comprises xylitol, and more particularly to an antipyretic preparation characterized in that it consists of an antipyretic and a synergistic amount of xylitol.
06/12/2003US20030109538 Pyrmidine derivatives as selective inhibitors of cox-2
06/12/2003US20030109504 Inhibit metabotropic glutamate receptor activity, or activation, for use in the treatment of movement disorders associated with a poverty of movement (e.g. Parkinson's disease). The compounds are particularly useful when used in
06/12/2003US20030109437 Peptides and methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using proteins (and peptides derived from the amino acid sequences of such
06/12/2003US20030109436 Wherein cysteine residue number 132 or 135 is replaced by another amino acid residue, preferably an alanine or serine residue and/or wherein the leucine residue at position 193 is the carboxy terminal residue. DNA sequence codes for cells
06/12/2003US20030108928 MID 241 receptor, a novel G-protein coupled receptor
06/12/2003US20030108651 Therapeutic and anti-oxidant for variety of health purposes, including treatment of skin damage; also useful as a natural antibacterial, antiviral and fungicidal agricultural product
06/12/2003US20030108493 Extracts from residues left in the production of wine
06/11/2003EP1317922A1 Antipyretic preparation containing xylitol
06/11/2003EP1317483A2 Variants of allergenic proteins of the group 2 of dermatophagoides
06/11/2003EP1317454A2 Caspase inhibitors and uses thereof
06/11/2003EP1317430A1 (2-azabicyclo 2.2.1]hept-7-yl)methanol derivatives as nicotinic acetylcholine receptor agonists
06/11/2003EP1317272A2 Composition for improving the cell protection comprising a lipophilic antioxidant an a hydrophilic antioxidant
06/11/2003EP1317266A2 Neuroprotective 2-pyridinamine compositions and related methods
06/11/2003EP1062349B1 Diisopropyl fluorophosphatase and the utilization and production thereof
06/11/2003CN1423559A Controlled-release compositions containing opioid agonist and antagonist
06/11/2003CN1423528A Nutritional modules
06/11/2003CN1422620A Aerosol for treating poisoning by nitrogen oxide and its use and preparation method
06/11/2003CN1111068C Strong anti-oxidative composite capsule of grape seed extract OPC and its production method
06/10/2003US6576624 Administering domperidone or pimozide jointly with miltefo-sine; reducing side effect of decrease in body weight
06/10/2003US6576268 Biologically active fraction of vegetable melanin, process for its production and its use
06/10/2003CA2413024A1 Antipyretic preparation containing xylitol
06/10/2003CA2192354C Corticotropin releasing factor against antagonist
06/10/2003CA2083505C New use of diphenylbutyl-piperazinecarboxamides in the treatment of substance disorders
06/05/2003WO2003045385A1 Benzothiazole derivatives
06/05/2003WO2003045372A1 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
06/05/2003WO2003045369A2 Use of l isomers of amino acid derivatives of hydroxyguanidine for producing no, pharmaceutical compositions containing same and pharmaceutical uses
06/05/2003WO2003045334A2 Methods and compositions for ameliorating the undesirable effects of chemotherapy
06/05/2003US20030105168 Composition comprising ubiquinone
06/05/2003US20030105104 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
06/05/2003US20030105031 Administering therapeutically effective amount of one or more flavonoids and carrier for therapy of reactive and inflammatory dermatoses
06/05/2003US20030105027 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
06/05/2003US20030104992 A cyclic polypeptides; immunosuppressive anti-inflammatory activity, inhibiting antigen-induced inflammatory cell infiltration
06/05/2003US20030103954 Comprises vitamin D3 for regulating cell differentiation and/or cell proliferation
06/05/2003US20030103953 Comprises vitamin D3 for controlling cell differentiation and/or cell proliferation
06/05/2003CA2467825A1 Benzothiazole derivatives
06/04/2003EP1316315A1 Medicinal compositions
06/04/2003EP1095007B1 Water-soluble zinc pyruvates or their hydrates, method for the production thereof and their use
06/04/2003EP0967987B1 Compositions for treating tumors containing shark cartilage extracts and anti-neoplastic agents
06/04/2003EP0606366B1 Substituted phenserines and phenylcarbamates of (-)-eseroline, (-)-n1-noreseroline, and (-)-n1-benzylnoreseroline; as specific inhibitors of acetylcholinesterase
06/04/2003CN1422230A Infusion packet with useful and decorative element, support member, delivery system and method
06/04/2003CN1421238A Natural bioreaction regulator with the functions of resisting cancer, resisting free radical damage and regulating immunity
06/04/2003CN1421138A Disinfectant tincture
06/03/2003US6573376 Solvent extraction; plant extracts
06/03/2003US6573265 Preventing or treating diseases caused by free radicals of the cellular oxygen metabolism, stimulating nerve cell growth, antagonizing glutamate receptors and/or stimulating the growth notably of glutamergic nerve cells; anticarcinogenic agents;
06/03/2003US6573264 Heteroaryl alkyl piperazine derivatives
06/03/2003US6573253 Methods for the administration of amifostine and related compounds
06/03/2003US6573244 Previns as specific inhibitors and therapeutic agents for Botulinum toxin B and Tetanus neurotoxins
05/2003
05/30/2003WO2003044024A1 4-(oxazolopyridin-2-yl)-1,4-diazabicyclo-[3.2.2]nonane derivatives, preparation and therapeutic use thereof
05/30/2003WO2003044012A1 N-formyl derivatives of paroxetine
05/30/2003WO2003043613A2 Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents
05/30/2003CA2464327A1 N-formyl derivatives of paroxetine
05/29/2003US20030100587 New substituted 2,4-thiazolidinedione derivatives, processes for producing them and pharmaceutical compositions containing them
05/29/2003US20030100542 5-hydroxysapogenin derivatives with anti-dementia activity
05/29/2003US20030099608 Human cytokine receptor
05/28/2003EP1313497A1 Use of extracts of the cassia alata plant
05/28/2003EP1313490A1 Pharmaceutical composition comprising wikstromol and/or matairesinol, its use as hepatoprotectant and process for their isolation from cedrus deodara
05/28/2003EP1313461A2 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands
05/28/2003EP1146885B1 Pre-conditioning against cell death
05/28/2003CN1420881A Beta-amino acid derivs. as inhibitors of matrix metalloproteases and TNF-alpha
05/28/2003CN1420782A Immune enhancing compositions
05/28/2003CN1419912A Cyanidenon, apigenin -7-0-beta-D-glucoside use and related medicine
05/22/2003WO2003042359A2 Histamine receptor h3 polynucleotides
05/22/2003WO2003042208A1 Pyrazole derivatives as psychopharmaceuticals
05/22/2003WO2003041736A2 Method for the treatment of cardiotoxicity induced by antitumor compounds
05/22/2003WO2003041499A2 Bactericides based on metal-chelate complexes and disinfecting composition
05/22/2003US20030096838 Novel triazolo-pyridines anti-inflammatory compounds
05/22/2003US20030096833 Use in inhibiting inflammation, cell death and in treating shock and reperfusion injuries
05/22/2003US20030096823 Method for the treatment of cardiotoxicity induced by antitumor compounds
05/22/2003US20030096758 Anticarcinogenic agents
05/22/2003US20030096756 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/22/2003US20030096737 Caspase inhibitors and uses thereof
05/22/2003US20030096350 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/22/2003CA2467347A1 Histamine receptor h3 polynucleotides
05/22/2003CA2467229A1 Dexrazoxane for treating antitumor-induced cardiotoxicity
05/22/2003CA2467081A1 Pyrazole derivatives as psychopharmaceuticals
05/21/2003EP1311684A1 Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them
05/21/2003EP1311525A2 Composition and method for inhibiting platelet aggregation
05/21/2003EP1311507A1 Fused pyrazole derivatives being protein kinase inhibitors
05/21/2003EP1311498A1 Diamino phenothiazine derivatives and composition comprising same
05/21/2003EP1311236A1 Use of beta-mannosylglycerate and derivatives in cosmetic and dermatological formulations
05/21/2003EP1233775B1 Tyrosine- and tryptophan-containing peptides as antioxidants
05/21/2003EP1173439B1 Haloalkoxy imidazonaphthyridines
1 ... 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 ... 191